Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Proteon Thera Com ST (PRTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.65 (-1.85%)
Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient

Stock Monitor: BioCryst Pharma Post Earnings Reporting

PRTO : 2.65 (-1.85%)
Proteon Therapeutics Announces First Quarter 2018 Financial Results

Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial...

PRTO : 2.65 (-1.85%)
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial...

PRTO : 2.65 (-1.85%)
Proteon Therapeutics to Present at Two Upcoming Investor Conferences

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.65 (-1.85%)
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase

Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it has...

PRTO : 2.65 (-1.85%)
Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.65 (-1.85%)
Proteon Therapeutics Announces Third Quarter 2017 Financial Results

Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced financial results...

PRTO : 2.65 (-1.85%)
Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017

Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company...

PRTO : 2.65 (-1.85%)
Proteon Therapeutics Announces Second Quarter 2017 Financial Results

Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced financial results...

PRTO : 2.65 (-1.85%)

Van Meerten Stock Picks

5 Great Large Caps
This morning I wanted to find 5 Large Cap stocks that had performed well over the last year and still appeared to have some juice left in them.
ABMD +2.93 , NFLX -0.89 , VLO -1.64 , RL +0.62 , ALGN -3.61
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed with most nearby contracts 1 to 2 cents lower on Friday, despite showing gains at midday. Front month July lost 4.37% on the week. December fell to within 1 1/4 cents of the life of contract low in the overnight session. Managed m...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar